Mitochondrial dysfunction underlying sporadic inclusion body myositis is ameliorated by the mitochondrial homing drug MA-5
Yoshitsugu Oikawa, Rumiko Izumi, Masashi Koide, Yoshihiro Hagiwara, Makoto Kanzaki, Naoki Suzuki, Koichi Kikuchi, Tetsuro Matsuhashi, Yukako Akiyama, Mariko Ichijo, Shun Watanabe, Takafumi Toyohara, Takehiro Suzuki, Eikan Mishima, Yasutoshi Akiyama, , Takaaki Abe
This study identifies mitochondrial dysfunction in sporadic inclusion body myositis and shows that MA-5 improves mitochondrial function and protects myoblasts.
PLoS ONE · Dec 2, 2020Peer-reviewedNeuroscience